Viemed Healthcare share price today

Viemed Healthcare, Inc.'s share price was $10.11 at the close on 4 November 2026. That is 5.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $12, and at that close it sat 63% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row.

Over the last 1 year the share price moved +50% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Viemed Healthcare, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Viemed Healthcare is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Viemed Healthcare, Inc. earned $2.8 M of net profit in the Jun 2026 quarter, −12.4% on the same quarter a year earlier. Full-year FY25 profit was $14.9 M. Over 4 years profit has grown 13.1% a year on average. That is 3.5% of the quarter's revenue. The same quarter a year earlier earned $3.2 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $14.9 M (+32.6% on the year before).

Why profit moved: revenue changed +23.9% on a year earlier and the margin moved −0.7 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +1.8% and revenue +25.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Viemed Healthcare, Inc. reported $78.1 M of revenue in the Jun 2026 quarter, +23.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 23.3% a year on average. The last full year, FY25, came in at $270 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $302 M.

FY25 revenue was $270 M, +20.5% on the year before.

Recent pace: the last four quarters grew +25.2% on average, against 23.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +25.2%, against +21.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +3.7%, against +23.8% a year (rolling over).

Viemed Healthcare, Inc.'s operating margin was 6.5% in the Jun 2026 quarter, 0.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between 6.0% and 9.0%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −0.7 percentage points on the year while gross margin changed −0.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 374% of Viemed Healthcare, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $51.9 M of operating cash against $14.9 M of profit. After $40.0 M of spending on assets, $11.9 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Viemed Healthcare, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $104 M on assets over the last 3 years. Averaged over those years that is 12.8% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $104 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Viemed Healthcare, Inc.'s P/E is 26.6×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 23.6×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +32.1% while the price moved +58.7%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Viemed Healthcare, Inc.'s business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +64.6% at its peak to +3.7%, but the business is still expanding, with ROCE rising at 16.8%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Viemed Healthcare, Inc. earned a ROE of 10% in FY25. That is up from a low of 6% in FY22. Its return on capital used (ROIC) is 2.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.5% net margin and 1.36× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 5.5% net margin × 1.36× asset turnover × 1.39× leverage (assets divided by equity) ≈ 10.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 12.7% − 9.9% = +2.8 percentage points. The 9.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 12.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 11.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Viemed Healthcare, Inc. has total debt of $11.6 M against shareholder equity of $146 M as of Jun 2026, so its debt is 0.08× its equity, which is very little. Year by year, that ratio went from 0.07 in FY21 to 0.11 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

5.0% of Viemed Healthcare, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Viemed Healthcare, Inc., the Z-score is 5.82. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 5.82 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Viemed Healthcare, Inc. is not among the largest members shown in this industry comparison for Medical Devices.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Viemed Healthcare is the 62nd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: SS Innovations International, Inc., BrainsWay and Orthofix Medical Inc. Just below it: Mobia Medical, Inc., CapsoVision, Inc. and ClearPoint Neuro, Inc.

Medical Devices companies close in size

59. SS Innovations International, Inc. $455 million
60. BrainsWay Ltd. $450 million
61. Orthofix Medical Inc. $396 million
62. Viemed Healthcare, Inc. $385 million
63. Mobia Medical, Inc. $374 million
64. CapsoVision, Inc. $343 million
65. ClearPoint Neuro, Inc. $326 million

All 75 Medical Devices companies, largest first

Companies close in size in other industries

3043. C&F Financial Corporation $361 million · Banks - Regional
3044. Northeast Community Bancorp, Inc. $360 million · Banks - Regional
3045. Viemed Healthcare, Inc. $360 million
3046. Waterdrop Inc. $359 million · Insurance - Diversified
3047. Orion Group Holdings, Inc. $359 million · Engineering & Construction

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.